RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR PEGCETACOPLAN COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR PEGCETACOPLAN COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Saved in:
Bibliographic Details
Published in:Hematology, Transfusion and Cell Therapy Vol. 42; pp. 12 - 13
Main Authors: H. Weitz, P. Hillmen, J. Szer, A. Röth, B. Höchsmann, J. Panse, K. Usuki, M. Griffin, J. Kiladjian, C. Decastro, H. Nishimori, L. Tan, M. Hamdani, P. Deschatelets, C. Francois, F. Grossi, A. Risitano, R.P. Latour
Format: Journal Article
Language:English
Published: Elsevier 01-11-2020
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:2531-1379
DOI:10.1016/j.htct.2020.10.021